US2023097580A1PendingUtilityA1

Compositions and methods for stimulating hair growth

62
Assignee: AMPLIFICA INCPriority: Feb 25, 2020Filed: Aug 25, 2022Published: Mar 30, 2023
Est. expiryFeb 25, 2040(~13.6 yrs left)· nominal 20-yr term from priority
Inventors:David RosenWilliam Rassman
A61P 17/14A61K 9/0019A61K 9/0014A61K 9/0021A61K 9/0009A61K 45/06A61K 38/1709A61K 31/728A61Q 7/00A61K 38/1754A61K 2800/591A61K 8/64A61K 2800/91A61K 2800/782A61K 8/735A61K 2800/81A61K 2800/83A61K 8/65A61K 2300/00A61M 37/0015A61K 38/19A61M 2037/0023A61K 38/191
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for stimulating hair growth are disclosed. Compositions for stimulating hair growth include two or more of hyaluronic acid, osteopontin, and another CD44 binding ligand. Methods for stimulating hair growth include administering such composition into the skin of a patient.

Claims

exact text as granted — not AI-modified
1 . A method of stimulating hair growth in a skin of a patient in need thereof, comprising: administering to the skin of the patient a composition comprising hyaluronic acid in a concentration of about 1 mcg/mL to about 250 mcg/mL and collagen. 
     
     
         2 . The method of  claim 1 , wherein the hyaluronic acid comprises an average molecular weight in a range of about 4,000 Da to 10,000 Da or in a range of about 20 KDa to 1350 KDa. 
     
     
         3 . The method of  claim 1 , wherein the hyaluronic acid is cross-linked and optionally wherein the cross-linked hyaluronic acid density is about 20% or greater. 
     
     
         4 . The method of  claim 1 , wherein the hyaluronic acid is present in a concentration of about 25 mcg/mL to about 250 mcg/mL. 
     
     
         5 . The method of  claim 1 , wherein the hyaluronic acid is present in a concentration of about 50 mcg/mL to about 250 mcg/mL. 
     
     
         6 . The method of  claim 1 , wherein the hyaluronic acid is present in a concentration of about 100 mcg/mL to about 250 mcg/mL. 
     
     
         7 . The method of  claim 1 , wherein the hyaluronic acid has a concentration of about 100 ug/mL or less. 
     
     
         8 . The method of  claim 1 , wherein the administering comprises injecting the composition into a dermal layer of the skin. 
     
     
         9 . The method of  claim 8 , wherein the composition is injected about 400 microns to about 2 mm deep into the skin. 
     
     
         10 . The method of  claim 8 , wherein the composition is administered in a plurality of injections in an amount of about 400 injections/cm.sup.2 skin to about 650 injections/cm.sup.2 skin. 
     
     
         11 . The method of  claim 1 , further comprising applying iontophoresis to the skin. 
     
     
         12 . The method of  claim 1 , further comprising applying electroporation to the skin. 
     
     
         13 . The method of  claim 1 , further comprising applying laser ablation to the skin. 
     
     
         14 . The method of  claim 1 , further comprising applying radiofrequency thermal ablation to the skin. 
     
     
         15 . The method of  claim 1 , further comprising applying a microneedle device to the skin. 
     
     
         16 . The method of  claim 1 , wherein the composition further comprises a CD44-binding ligand. 
     
     
         17 . The method of  claim 16 , wherein the CD44-binding ligand is osteopontin. 
     
     
         18 . A method of administering a composition for hair growth to a patient in need of treatment for hair loss comprising: injecting the composition into a skin of the patient, wherein the composition comprises hyaluronic acid in a concentration of about 1 mcg/mL to about 250 mcg/mL and collagen. 
     
     
         19 . The method of  claim 18 , wherein the hyaluronic acid comprises an average molecular weight in a range of about 4,000 Da to 10,000 Da or in a range of about 20 KDa to 1350 KDa. 
     
     
         20 . The method of  claim 18 , wherein the hyaluronic acid is cross-linked and optionally wherein the cross-linked hyaluronic acid density is about 20% or greater. 
     
     
         21 . The method of  claim 18 , wherein the hyaluronic acid is present in a concentration of about 25 mcg/mL to about 250 mcg/mL. 
     
     
         22 . The method of  claim 18 , wherein the hyaluronic acid is present in a concentration of about 50 mcg/mL to about 250 mcg/mL. 
     
     
         23 . The method of  claim 18 , wherein the hyaluronic acid is present in a concentration of about 100 mcg/mL to about 250 mcg/mL. 
     
     
         24 . The method of  claim 18 , wherein the hyaluronic acid has a concentration of about 100 ug/mL or less. 
     
     
         25 . The method of  claim 18 , wherein the administering comprises injecting the composition into a dermal layer of the skin. 
     
     
         26 . The method of  claim 25 , wherein the composition is injected via a needle, and wherein the needle is inserted 400 microns to about 2 mm into the skin before injection. 
     
     
         27 . The method of  claim 26 , wherein the needle is a microneedle. 
     
     
         28 . The method of  claim 18 , wherein the composition further comprises a CD44-binding ligand. 
     
     
         29 . The method of  claim 28 , wherein the CD44-binding ligand is osteopontin.

Join the waitlist — get patent alerts

Track US2023097580A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.